Surgery for colorectal peritoneal carcinomatosis

Area of Science:

• Oncology
• Surgical Oncology
• Gastroenterology

Background:

• Peritoneal carcinomatosis is a severe complication of advanced cancers, significantly reducing patient survival.
• Systemic chemotherapy alone is insufficient for managing peritoneal carcinomatosis.
• Recurrence after primary tumor treatment often leads to peritoneal carcinomatosis.

Purpose of the Study:

• To review the advancements in understanding and treating peritoneal surface malignancy, specifically from colorectal cancer.
• To summarize the survival benefits of combining cytoreductive surgery and intraperitoneal chemotherapy.
• To highlight the role of novel surgical and chemotherapeutic techniques.

Main Methods:

• Cytoreductive surgery using peritonectomy procedures for complete tumor eradication.
• Intraperitoneal chemotherapy regimens, including intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC).
• Review of current literature documenting survival benefits.

Main Results:

• Cytoreductive surgery effectively removes peritoneal tumors.
• HIPEC and EPIC are effective adjuvant treatments for minimal residual disease post-surgery.
• Combination therapy significantly improves survival for patients with peritoneal carcinomatosis.

Conclusions:

• Combining cytoreductive surgery with intraperitoneal chemotherapy is a proven strategy for improving survival in peritoneal carcinomatosis.
• HIPEC and EPIC are crucial in reducing locoregional recurrence after cytoreductive surgery.
• This multimodal approach represents a significant advancement in treating advanced peritoneal surface malignancy.